| Literature DB >> 35655641 |
Akshay Samagani1, Leena Raveendra1, Belliappa P Raju1.
Abstract
Context: Molluscum contagiosum (MC) is a common viral cutaneous infection. Despite multiple treatment options, there is no definitive treatment. In some cases, the lesions are severe, recurrent, and cosmetically odd. Modified autoinoculation (MAI) is a novel technique that induces cell-mediated immunity resulting in clearance of local as well as distant lesions. Potassium hydroxide (KOH) acts by dissolving the keratin and penetrating deeply destroys the hyperproliferative tissue. We would here like to compare MAI with topical KOH in the treatment of MC. Aims and Objective: The aim of this study was to assess the effectiveness of MAI in treatment of MC and to compare its response with topical KOH application. Settings and Design: This was an open-labeled longitudinal therapeutic outcome study carried out at a tertiary care center over a period of 1 year. Materials andEntities:
Keywords: Modified autoinoculation; Modified autoinoculation therapy is a promising treatment option in treating severe, recurrent, extensive, and recalcitrant molluscum contagiosum infections. Modified autoinoculation is a safe, highly effective, and immune-stimulating mode of therapy that can cause resolution of lesions at distant sites also.; molluscum contagiosum; potassium hydroxide
Year: 2022 PMID: 35655641 PMCID: PMC9153309 DOI: 10.4103/JCAS.JCAS_228_20
Source DB: PubMed Journal: J Cutan Aesthet Surg ISSN: 0974-2077
Figure 1Flow chart of the progress of study through various phases
Figure 2(A) An insulin syringe used to puncture MC lesion deep into the dermis, along all the axes and planes of a fully developed lesion. (B) Multiple bleeding points from the site of entry. (C) A mild compression by rotatory movements with a cotton swab
Comparison of number of lesions at different weeks of follow-up in modified autoinoculation method and topical potassium hydroxide treatment group
| Modified autoinoculation method Mean ± SD | Topical potassium hydroxide Mean ± SD | ||
|---|---|---|---|
| Week 1 follow-up | 27.1 ± 14.54 | 24.84 ± 14.46 | . 439(NS) |
| Week 2 follow-up | 17.56 ± 11.64 | 19.86 ± 12.49 | .352(NS) |
| Week 4 follow-up | 7.34 ± 7.23 | 11.84 ± 9.11 | .009** |
| Week 8 follow-up | 2.21 ± 3.9 | 5.45 ± 5.68 | .002** |
| Week 12 follow-up | 0.64 ± 1.81 | 1.81 ± 4.14 | .042* |
| Week 16 follow-up | 0.32 ± 1.2 | 1.41 ± 3.81 | .01* |
NS = nonsignificant
*P <0.05 is statistically significant
**Highly significant
Figure 3Graph depicting average number of lesions among both the groups, on follow-up
Complete resolution of the MC in patients at successive follow-up during the study
| Method | Week 4 | Week 8 | Week 12 | Week 16 |
|---|---|---|---|---|
| Modified autoinoculation method ( | 15(31.91%) | 30(63.82%) | 39(82.97%) | 43(91.48%) |
| Topical potassium hydroxide ( | 8(16.33%) | 17(34.70%) | 34(69.40%) | 40(81.64%) |
| 0.082797(NS) | 0.005617* | 0.160605(NS) | 0.231536(NS) |
NS = nonsignificant
*P < 0.005 is highly significant
Figure 4Responses to modified autoinoculation on day 0 (A, C, and E) and complete resolution at the end of 16th week (B, D, and F) follow-up
Figure 5Responses to topical potassium hydroxide on day 0 (A, C, and E) and complete resolution at the end of 16th week (B, D, and F) follow-up